YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Abstract YIV-906 (PHY906) is a standardized botanical cancer drug candidate developed with a systems biology approach—inspired by a traditional Chinese herbal formulation, historically used to treat gastrointestinal symptoms including diarrhea, nausea and vomiting. In combination with chemotherapy a...
Guardado en:
Autores principales: | Xiaochen Yang, Wing Lam, Zaoli Jiang, Fulan Guan, Xue Han, Rong Hu, Wei Cai, William Cheng, Shwu-Huey Liu, Peikwen Cheng, Yuping Cai, Nicholas J. W. Rattray, Caroline H. Johnson, Lieping Chen, Yung-Chi Cheng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ae2979734ecc4108a42ccbc05970d901 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Acta Nº906
por: Banco Central de Chile
Publicado: (2019) -
Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906)
por: Scherzinger-Laude K, et al.
Publicado: (2013) -
A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma
por: Junyu Huo, et al.
Publicado: (2021) -
Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906
por: Kazuki Tajima, et al.
Publicado: (2017) -
Majority of Chinese Medicine Herb Category “Qing Re Yao” Have Multiple Mechanisms of Anti-inflammatory Activity
por: Fulan Guan, et al.
Publicado: (2018)